Articles tagged with Hormone Therapy
A recent study published in the American Journal of Neuroradiology found that women with mild cognitive impairment experience higher rates of cognitive decline than men, while all women exhibit greater regional brain loss over time. The study's authors suggest that hormonal differences may play a role in these findings.
Researchers at the University of Montreal found that a liver protein plays a crucial role in pregnancy and the human menstrual cycle. The study, published in Nature Medicine, showed that mice genetically engineered to lack the protein had defective placentas and failed pregnancies.
A large analysis of the Women's Health Initiative trial found that combining hormone therapy with calcium and vitamin D supplements significantly reduces the risk of hip fractures. The study suggests that women taking postmenopausal hormone therapy should consider taking these supplements to boost bone health.
Patients with Type 2 diabetes who start on three medications at diagnosis have better glucose control with lower hemoglobin A1c levels and fewer hypoglycemic events compared to conventional therapy. The triple-therapy regimen also promotes weight loss and preserves beta cell function.
A study of postmenopausal hormone therapy found no long-term benefits or risks to cognitive function in women aged 50-55. Cognitive assessments conducted 7.2 years after treatment cessation showed similar global and domain-specific cognitive functioning between those who received hormone therapy and placebo.
A new study reveals that British post-menopausal women are 50% less likely to access appropriate treatment for vaginal atrophy, a chronic condition caused by low estrogen levels. The condition can lead to painful intercourse and emotional distress, but local oestrogen therapy has shown beneficial effects on sex lives.
A multicenter European study found that short-term hormonal therapy for transsexualism is effective and safe, with few side effects. The treatment, which involves large doses of male or female sex hormones, was shown to be effective in changing the external characteristics of trans individuals.
A new study suggests that testosterone therapy can reduce pain perception and tolerance in men with low testosterone levels caused by opioid pain relievers. The study found significant improvements in pain sensitivity during laboratory pain testing after testosterone administration compared to placebo.
A clinical study found that kisspeptin effectively induces egg maturation in women undergoing IVF treatment, reducing the risk of ovarian hyperstimulation syndrome. The hormone triggers natural reproductive hormone release, resulting in healthy babies.
A new study published in The Endocrine Society's Annual Meeting found that testosterone therapy improved verbal learning and memory in postmenopausal women compared to placebo. Testosterone levels increased with treatment but remained within normal female range, with no major side effects reported.
A new study finds desiccated thyroid extract (DTE) to be a safe and effective alternative to standard T4 therapy for hypothyroid patients. DTE caused modest weight loss and nearly half of the study patients preferred it over L-T4.
A clinical study found that high-dose testosterone significantly improves sexual function among women who have had their uterus and ovaries removed. Women receiving 25mg of testosterone experienced improved blood concentrations of free testosterone, related to increased sexual encounters.
A new study presented at The Endocrine Society's Annual Meeting found that hormone treatment to halt puberty in transgender adolescents is effective and safe, relieving psychological suffering. After cross-sex hormone therapy, bone density caught up, similar to natural puberty, with no long-term harm detected.
Researchers discovered a molecular switch, Steroidogenic Factor 1, that stimulates steroid hormone production and cell multiplication in aggressive prostate cancers. This factor increases tumor growth and resistance to hormone treatment.
A study shows that bazedoxifene, an approved osteoporosis drug, inhibits estrogen-induced gene expression and cell proliferation in breast cancer cells. The medication also reduced estrogen activity and estrogen receptor levels in cultured human breast cancer cells.
A new study published in Cancer Discovery identified two genetic variations associated with breast cancer risk in women receiving preventive therapy. Women with favorable variations were more likely to respond to the therapy, while those with unfavorable variations had a five-fold increased risk of developing breast cancer.
Researchers identified genetic variations associated with breast cancer risk among women on tamoxifen and raloxifene therapy. Women with favorable variations of the ZNF423 and CTSO genes are more likely to respond to prevention therapy, while those with unfavorable variations face a five-fold increased risk of developing breast cancer.
A new study reveals that hormonal treatment for endometrial cancer works by binding to stromal tissue cells, rather than directly targeting cancerous cells. Researchers hope to develop a simple test to determine patient suitability for progesterone therapy.
A study found that testosterone therapy prescriptions increased significantly over 10 years, with 2.29% of men in their 40s and 3.75% of men in their 60s taking some form of testosterone therapy. The trend is driven by direct-to-consumer marketing campaigns and the expansion of low-T centers.
Researchers at Stanford University and Akira University in Japan have discovered a new hormone called R-spondin2 that promotes follicle development and stimulates ovary growth. The hormone, produced by human female eggs, may lead to new infertility treatment options when used with traditional Follicle Stimulating Hormone (FSH).
Researchers at Monash University have identified a sub-group of cells that can contribute to prostate cancer recurrence, opening up new treatment options. These previously unidentified cells are potential targets for future therapies and may be targeted before the cancer reaches an incurable stage.
Research presented at the Heart Failure Congress 2013 found that heart failure accelerates the natural process of aging and favours early onset of male 'menopause', also known as andropausal syndrome. The prevalence of AS was four times higher in men with heart failure compared to healthy peers.
The British Menopause Society and Women's Health Concern have released updated guidelines on Hormone Replacement Therapy (HRT), providing clearer guidance on its role, benefits, and risks. The new recommendations aim to optimize clinical decisions and offer balanced advice for health professionals and women considering HRT treatment.
A new study published in The Journal of Physiology found that hormone replacement therapy (HRT) significantly improves muscle function down to the muscle fibre level in postmenopausal women. HRT has been shown to reduce age-related decline in muscle mass and strength, particularly at cellular and molecular levels.
A new study has found that about 42% of veterans returning from Afghanistan and Iraq with blast injuries have irregular hormone levels indicative of hypopituitarism. The condition can mimic symptoms of PTSD, depression, and other conditions, but is often unrecognized and treatable by replacing deficient hormones.
Research found that low-vitamin D season can reduce breast cancer treatment effectiveness by up to 30%. The study identifies seasonal and genetic factors affecting tamoxifen metabolism.
A multicenter study found that 84% of lung cancer patients taking crizotinib have low testosterone levels, with 80% experiencing symptoms such as sexual dysfunction or depression. The study suggests that hormone replacement therapies may alleviate these symptoms and provide a new treatment option for affected patients.
A study of 40 patients on high-dose opioid therapy found improved pain control and mental outlook, but also significant hormonal disturbances and signs of inflammation. Despite these complications, the majority of patients reported improvements in at least one physiologic function.
Breast cancers with high androgen receptor (AR) levels are more likely to relapse after estrogen-targeting therapies. Anti-androgen therapy shows promising responses in cell lines and preclinical models, offering a new potential target for breast cancer treatment.
A study found that growth hormone therapy can help reverse growth problems in children with kidney failure by increasing bone turnover. However, treatment may not benefit overall bone health and may interrupt the relationship between bone turnover and parathyroid hormone markers.
A new study of 1,535 patients with metastatic hormone-sensitive prostate cancer found that taking breaks from hormone-blocking treatments may not be as effective as continuous treatment. The study suggests that patients should be counseled about the potential risks of intermittent therapy if they wish to try it.
A study published in the New England Journal of Medicine recommends continuous hormone therapy for metastatic prostate cancer, extending lives by months to years. Continuous therapy offers a better alternative to intermittent therapy with fewer side effects.
Researchers at Princess Margaret Cancer Centre identify Notch signalling pathway as key driver of resistance to hormone therapies in ER-positive breast cancer cells. A companion prognostic test is proposed to predict tumour response to new therapy.
A study published in the Journal of the National Cancer Institute found that estrogen plus progestin use is associated with an increased risk of breast cancer incidence. However, survival after diagnosis did not differ between users and non-users, suggesting higher mortality rates among hormone therapy users.
A recent study published in the Journal of the National Cancer Institute found that estrogen plus progestin use is associated with an increased risk of breast cancer. The study suggests that mortality from breast cancer may be higher for women using this combined hormonal therapy.
Women who undergo surgical menopause experience a two-fold increase in cognitive decline and dementia due to premature estrogen loss. Research suggests that this leads to increased sensitivity to stressors and abnormal protein production, which can contribute to Alzheimer's disease. Follow-up studies are needed to confirm the findings.
Researchers identified a specific cell membrane protein blocking cell death in hormone-therapy-related breast cancers, which could be targeted by new therapies. Progestin, a synthetic hormone used in hormone replacement therapy, affects the protein's activity and increases cancer risk.
Researchers found increased cell proliferation and alpha-cell expansion in pancreases of individuals with Type 2 diabetes treated with incretin therapy, a widely used type of treatment. The study suggests a possible link between GLP-1-based therapies and an increased risk of neuroendocrine tumors.
A large-scale study found that oral estrogen therapy increases the risk of gallbladder surgery in postmenopausal women. Women using transdermal therapies like patches or gels were not at increased risk.
A study by Sanford-Burnham researchers found that Siah2 keeps androgen receptors constantly active in prostate cancer cells, enabling them to survive treatment. Inhibiting Siah2 may provide a new method for re-sensitizing castration-resistant prostate tumors to hormone therapy.
A recent study published in the Journal of Family Planning and Reproductive Health Care analyzed data from three major studies on hormone replacement therapy (HRT) and found no clear evidence linking its decline to a decrease in breast cancer rates. The authors point out methodological flaws in the original studies, including detection...
A new study found that adrenocorticotropic hormone (ACTH) may be effective in treating people with breakthrough multiple sclerosis. Participants who received ACTH had fewer relapses and no psychiatric side effects, compared to those receiving methylprednisolone.
A study published in the Journal of Translational Medicine found that thyroid hormone treatment reduced loss of heart muscle cells and improved heart function in rats after a heart attack. The researchers believe this could lead to improved patient outcomes and significant healthcare savings.
A modified Newcastle disease virus has been developed to target prostate cancer cells without harming normal cells, offering a new treatment option for hormone-refractory patients. This oncolytic virus uses a retargeted design to minimize off-target losses and reduce the amount of virus needed for treatment.
A recent study found that rural sewage lagoons can effectively remove most commonly used pharmaceuticals and hormones from wastewater, but some compounds persist in the environment. The study, led by Wei Zheng, suggests that increased concentrations of PPCPs were detected in November samples due to warmer temperatures.
Researchers have discovered a vast potential for noncoding RNAs to be used as therapeutic and diagnostic tools. Long noncoding RNAs play significant roles in various diseases, including cancer, diabetes, and other conditions. The emerging concept of microRNAs functioning as hormones has also led to new avenues for disease treatment.
A new progestogen-only treatment has been found to halt acute abnormal uterine bleeding in women, with 44 of 48 participants experiencing complete cessation of bleeding within five days. The therapy, which involves a low-dose injection and oral pills, shows promise as a temporary bridge to longer-term targeted therapies.
A study found that healthy menopausal women with an Alzheimer's risk factor showed accelerated biological aging, but hormone therapy reversed this effect. The research used telomere length as a measure of biological aging and found that estrogen therapy protected against this aging process.
Researchers found that estrogen levels can affect infection susceptibility, bladder health and the inflammatory response to infection in mice with simulated menopause. Boosting estrogen levels may get a second look as an approach for reducing urinary tract infections in menopausal women.
A study of 1,837 women found that early surgical menopause is associated with faster declines in long-term memory and overall thinking abilities. Women on hormone replacement therapies had slower declines.
Herbal and complementary medicines can effectively treat postmenopausal symptoms without the risks associated with hormone replacement therapy. Soy, red clover, and black cohosh have been shown to ease hot flush symptoms and other menopausal issues, making them viable alternatives for women seeking non-pharmacological treatment options.
A new hormone therapy combining conventional estrogen with a bone-protective SERM-like drug has shown promise in reducing menopausal symptoms and osteoporosis risk without increasing breast cancer risk. The treatment approach, termed TSEC, was tested in postmenopausal nonhuman primates over a 20-month period.
A study by Vanderbilt-Ingram Cancer Center investigators found that most triple-negative breast cancer patients have multiple genetic mutations, despite treatment with chemotherapy. The research may provide targets for new therapies and shed light on the challenges of treating this form of cancer.
A study conducted by Elizabeth Nedstrand and Lotta Lindh-Åstrand found that applied relaxation therapy reduced hot flushes in postmenopausal women by half. The treatment also showed improvements in quality of life, particularly in memory, concentration, sleep, and anxiety.
The American College of Physicians releases new clinical practice guidelines for stable ischemic heart disease, emphasizing patient education and risk factor modification. The guidelines address initial cardiac testing, management, and follow-up care for patients with stable IHD.
Researchers at Indiana University found a way to combine two hormones into a single molecule, producing more effective weight loss with fewer side effects. The hormone combination targets the hypothalamus and pancreas, reducing the risk of cancer and stroke.
A new study conducted at Baylor University's Mind-Body Medicine Research Laboratory found that hypnotic relaxation therapy significantly reduced hot flashes in postmenopausal women, with a decrease of up to 80% reported. The treatment also showed improvements in quality of life and reductions in anxiety and depression.
Men treated with proton therapy for prostate cancer reported excellent urinary and bowel function, similar to healthy controls. However, sexual function was affected by hormone therapy and other factors, with significant differences noted between groups.
Researchers at Moffitt Cancer Center have found that men with prostate cancer who receive androgen deprivation therapy are susceptible to heightened fatigue if they carry specific variants of the IL6 and TNFA genes. This discovery highlights the importance of personalized medicine in tailoring therapies to a patient's genetic profile.
A new study suggests that hormone therapy initiated close to menopause can reduce the risk of developing Alzheimer's disease. Women who began hormone therapy within five years of menopause had a 30% lower risk of Alzheimer's dementia than those who did not use hormone therapy.